dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
dc.contributor.author |
Massanella, Marta |
dc.contributor.author |
Ouchi, Dan |
dc.contributor.author |
Marfil, Sílvia |
dc.contributor.author |
Llibre, Josep M. |
dc.contributor.author |
Puertas, M.C. |
dc.contributor.author |
Buzon, Maria J. |
dc.contributor.author |
Richman, Douglas D. |
dc.contributor.author |
Orna, Elisa |
dc.contributor.author |
Stevenson, Mario |
dc.contributor.author |
Gatell, J.M. |
dc.contributor.author |
Domingo, Pere |
dc.contributor.author |
Negredo, Eugenia |
dc.contributor.author |
Martinez Picado, Francisco Javier |
dc.contributor.author |
Clotet, Bonaventura |
dc.contributor.author |
Blanco, Julià |
dc.date |
2014 |
dc.identifier |
Massanella, M., Ouchi, D., Marfil, S., Llibre, J. M., Puertas, M. C., Buzon, M. J., et al. (2014). Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. Plos One, 9(12), e114142. |
dc.identifier |
1932-6203 |
dc.identifier |
http://hdl.handle.net/10854/3808 |
dc.identifier |
https://doi.org/10.1371/journal.pone.0114142 |
dc.identifier.uri |
http://hdl.handle.net/10854/3808 |
dc.description |
Abstract
Background
HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies.
Methods
Longitudinal plasma samples (0–48 weeks) from the IntegRal (n = 67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts<350 cells/µl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis.
Results
At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P = 0.040).
Conclusions
The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers. |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
Public Library of Science |
dc.rights |
Aquest document està subjecte a aquesta llicència Creative Commons |
dc.rights |
http://creativecommons.org/licenses/by/3.0/es/ |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Sida -- Tractament |
dc.title |
Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/publishedVersion |